NextPlat Opens PharmcoRx Pharmacy in Jacksonville, FL

NextPlat Corp. (NXPL) opened a new PharmcoRx pharmacy in Jacksonville, FL, expanding its network to six locations. The pharmacy offers prescription services, 340B program support, and specialty care. The company recently acquired a pharmacy near Pensacola for $1.49M, aiming to diversify its services and reduce reliance on single channels.

Original reporting
Published Oct 15, 2026, 7:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
NextPlat Opens PharmcoRx Pharmacy in Jacksonville, FL — source image
Decision brief

The 30-second read

$NXPLBullishLow
01

Why it matters

For traders, the key takeaway is operational expansion into a new geography plus added contracted-service lines (340B, long-term care, specialty services). However, the piece does not provide incremental financials, margins, or guidance tied specifically to Jacksonville.

02

Market read

A newly opened Jacksonville pharmacy adds retail presence and contracted 340B and institutional capabilities, but lacks financial magnitude, making it more of a slow-burn growth signal than a near-term catalyst.

03

What to watch

Execution risk exists around 340B compliance carve-outs (Medicaid carve-out rules) and whether long-term care and specialty services are fully operational immediately.

Relevance 5/10Novelty 4/10Timing: immediate, as the Jacksonville pharmacy opening is newly announced

Background

The article describes PharmcoRx, NextPlat’s Florida pharmacy network, and situates the Jacksonville opening within a broader Florida footprint expansion that also included a recent Pensacola-area acquisition.

Company-level read

Ticker impact

$NXPLBullishMedium confidence
Context

NextPlat’s PharmcoRx opened a new Jacksonville pharmacy and will provide 340B contracted services, expanding its Florida retail and higher-margin offerings.

Expected impact

Likely mild positive bias as investors price continued footprint expansion and added contracted-service capabilities.

Evidence & confidence

The article is a company-specific expansion update with operational details (340B, long-term care, specialty services) but no financial guidance or deal size for the Jacksonville opening, limiting near-term magnitude.

Market effects

Highlights ongoing demand for contract pharmacy and 340B-enabled services, reinforcing the business model for pharmacy networks serving safety-net providers.

In Jacksonville, proximity to a major hospital and nearby specialty practices may improve patient capture and provider relationships for PharmcoRx.

Limited, as the news is primarily a US retail and contracted-services expansion.

Counterpoint

Without disclosed ramp timing or financial contribution for the Jacksonville site, the market may treat it as incremental and not a material earnings driver.

Key entities

  • NextPlat Corp.

    Nasdaq-listed parent of the PharmcoRx pharmacy network, expanding retail and contracted pharmacy services in Florida.

  • PharmcoRx

    NextPlat’s pharmacy network operating retail pharmacies and contracted services including 340B support.

  • HCA Florida Memorial Hospital

    Hospital campus across from the new Jacksonville pharmacy location.

Related articles

$NXPLMed

NextPlat Reports 21% Sequential Quarterly Revenue Growth, 87% Reduction in Quarterly Net Loss to $144,000 and Record Gross Margin of Approximately 40%

NextPlat Corp (NXPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NextPlat Reports 21% Sequential Quarterly Revenue Growth, 87% Reduction in Quarterly Net Loss to $144,000 and Record Gross Margin of Approximately 40% Growth Momentum Continues Across the Business, Highlighted by Increased Higher-Margin 340B Healthcare Prescription V

$NXPLMedAI 8/10

NextPlat Reports 21% Sequential Quarterly Revenue Growth, 87% Reduction in Quarterly Net Loss to $144,000 and Record Gross Margin of Approximately 40%

NextPlat Corp (NASDAQ: NXPL) reported Q2 2026 results ended June 30. Revenue was about $11.9M, up 21% sequentially. Net loss fell 92% to about $144K. Gross margin reached a record ~40% (Healthcare segment ~46%). Contracted pharmacy revenue rose 136% to ~$2.2M. The company also said it plans a Pensacola-area pharmacy acquisition.

$NXPLHighAI 9/10

NextPlat (NXPL) Q1 2026 Earnings Transcript

NextPlat (NXPL) reported Q1 2026 net revenues of $10 million, down from $14 million a year earlier, citing restructuring and reimbursement changes. Healthcare revenue was $7 million; pharmacy contract revenue rose to $1.9 million. Gross margin increased to 35% and operating loss narrowed to $1.1 million. Cash was $11 million with no meaningful debt; the company also noted a reverse split and new 340B agreements.